Learning Objective
- Illustrate the Indian pharmaceutical and intellectual property environment; and highlight the tradeoffs faced by startups expanding into new sectors.
Abstract
Biocon India Group has just formed a new subsidiary, Clinigene, to provide services in clinical trials. Concerns abound, however, as to whether this new subsidiary could prove to be a distraction or worse to this enzyme and pharmaceutical manufacturer.
Appropriate for the Following Course(s)
Global entrepreneurship, Strategy
Biocon India Group
THERE IS NO TEACHING NOTE FOR THIS CASE STUDY.